- Investing Ideas
- /
- Hong Kong Pharmaceuticals & Biotech Undervalued based on future growth
Hong Kong Pharmaceuticals & Biotech Undervalued based on future growth
Results
5
Companies which can be considered undervalued when accounting for expected future growth (PEG under 0.8)
5 companies
China Resources Pharmaceutical Group
Market Cap: HK$28.6b
An investment holding company, engages in the manufacture, distribution, and retail of pharmaceutical and other healthcare products in Mainland China and internationally.
3320
HK$4.60
7D
1.3%
1Y
-11.0%
Shanghai Haohai Biological Technology
Market Cap: HK$10.8b
Shanghai Haohai Biological Technology Co., Ltd.
6826
HK$25.72
7D
0.8%
1Y
3.1%
Tong Ren Tang Technologies
Market Cap: HK$5.6b
Produces and distributes Chinese medicine products in Mainland China and Hong Kong.
1666
HK$4.36
7D
-1.6%
1Y
-10.5%
Essex Bio-Technology
Market Cap: HK$2.3b
An investment holding company, develops, manufactures, and sells biologic drugs in China, Hong Kong, and internationally.
1061
HK$4.17
7D
-3.2%
1Y
48.4%
JBM (Healthcare)
Market Cap: HK$2.3b
An investment holding company, engages in the manufacture, marketing, distribution, and sale of branded healthcare and wellness products in Hong Kong, Macau, Mainland China, and internationally.
2161
HK$2.75
7D
-1.4%
1Y
44.0%